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Objective: This study assessed incidence, aetiology, clinical outcomes and risk factors for
community-acquired pneumonia (CAP) in older adults.
Methods: This was a population-based cohort study that included 11,241 community-dwelling
individuals aged 65 years or more, who were followed between 2002 and 2005 in the region of
Tarragona, Spain. Primary endpoints were all-cause CAP (hospitalised and outpatient) and 30-
day mortality after the diagnosis. All cases were radiographically proved and validated by
checking clinical records.
Results: Incidence rate of overall CAP was 14 cases per 1000 person-years (10.5 and 3.5 for
hospitalised and outpatient cases, respectively). Incidence was almost three-fold higher
among immunocompromised patients (30.9 per 1000) than among immunocompetent subjects
(11.6 per 1000). Maximum incidences were observed among patients with chronic lung disease
and long-term corticosteroid therapy (46.5 and 40.1 cases per 1000 person-years, respec-
tively). Overall 30-day case-fatality rate was 12.7% (2% in cases managed as outpatient and
15% in hospitalised patients). Among 358 patients with an aetiological work-up, a total of
142 pathogens were found (single pathogen in 121 cases and mixed pathogens in 10 cases).
Streptococcus pneumoniae was the most common pathogen (49%), followed by Pseudomonas
aeruginosa (15%), Chlamydia pneumoniae (9%) and Haemophilus influenzae (6%). In multivari-
able analysis, the variables most strongly associated with increasing risk of CAP were history of
hospitalisation for CAP in the previous 2 years and presence of any chronic lung disease.
Conclusions: CAP remains a major cause of morbidity and mortality in older adults. Incidence
rates in this study largely doubled prior rates reported in Southern European regions.
ª 2008 Elsevier Ltd. All rights reserved.7 240666; fax: þ34 977 226411.
ncat.cat (A. Vila-Corcoles).
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310 A. Vila-Corcoles et al.Introduction members and validate cases of outpatient CAP occurredCommunity- acquired pneumonia (CAP) remains an important
cause of morbidity and mortality, especially in older adults
and patients at-risk.1e3 Nowadays, CAP cases in older adults
increase as a consequence of an overall increase in the elderly
population (persons aged 65 years or older).4 In developed
countries, almost one half of the total hospitalisations for
pneumonia occurs in patients over 65 years and pneumonia is
a leading cause of death among this age group.2,3,5e7
However, despite the recognised importance of CAP in
the elderly, information on its epidemiology in this age
group is limited. Most epidemiological data has been
obtained from studies on CAP patients admitted in hospi-
tals,5e11 and few studies focusing on the possible contri-
bution of outpatient cases have been reported.12e15
Controversy about the epidemiology of CAP still exists and
more epidemiological studies are needed.
In this study, we have assessed incidence, aetiology and
clinical characteristics of CAP (hospitalised and outpatient
cases) in a large cohort of 11,241 Spanish community-
dwelling elderly individuals followed during a consecutive 40-
month study period. This work is a part of the EVAN-65 Study,
whose results evaluating pneumococcal vaccine effective-
ness in elderly people have already been published.16Methods
Design, setting and study population
This was a population-based cohort study focused on
elderly people assigned to eight Primary Health Care
Centres (PHCC) in the region of Tarragona, a mixed resi-
dential-industrial urban region on the Mediterranean coast
of Catalonia, Spain.
The study cohort included all community-dwelling indi-
viduals assigned to the eight participating PHCCs, who were
65 years or older at the start of the study (an amount of
11,241 individuals with a mean age of 74.6 [SD:7.5] years-
old at baseline) The study was approved by the ethical
committee of the Catalonian Health Institute and was
conducted in accordance with the general principles for
observational studies set out by the institution.
Cohort members were followed from when the study
started (January 1, 2002) until the occurrence of the first
event, the enrolment from the PHCC ceased, death, or until
the end of the study (April 30, 2005). Mean temperatures
in the study area for summer and winter seasons throughout
the study period were 23.2 C (73.8 F) and 9.8 C (49.6 F),
respectively.
Sources of data
All participating PHCCs had a computerised clinical record
system (working since 1999 or before) with registries of
administrative data, medical conditions and diagnoses
associated with outpatient visits coded according to the
International Classification of Diseases, 9th Revision, Clin-
ical modification (ICD-9). This electronic clinical record
system was used to identify underlying conditions in cohortduring the survey. Additionally, the hospital discharge
diagnoses database and the clinical medical records of the
three participating reference hospitals in the study area
(Joan XXIII, Santa Tecla, and Pius Hospital) were used to
identify and validate hospitalisations for CAP in cohort
members during the study period.
Outcome measure and definitions
Primary endpoints were CAP and death from CAP. Pneu-
monia was defined when a new radiological infiltrate was
identified with one of major criteria (cough, expectoration
or fever) or two of minor criteria (dyspnoea, pleuritic pain,
altered mental status, pulmonary consolidation on auscul-
tation and leukocytosis). Death from pneumonia (case-
fatality) was considered when the patient died (in-hospital
or not) within the first 30 days after the diagnosis.17,18
Hospitalisations for CAP were identified on the basis of
first-listed code in the hospitals discharge databases (ICD-9:
480e487). Outpatient CAP was a primary care or emergency
visit with an ICD-9 code registered for pneumonia in the
PHCCs databases. All pneumonia cases (hospitalised and
outpatient) were radiographically confirmed and validated
by checking clinical records with the use of a standardised
data collection instrument (which included sociodemo-
graphical, clinical, exploratory, analytical and radio-
graphical data at the time of diagnosis). Pneumonia
Severity Index (PSI) was calculated according to criteria
described in classical meta-analysis.17
Since the beginning of the study, conventional diagnostic
work-ups to identify different microorganisms causing pneu-
monia included blood cultures, sputum cultures and sero-
logical testing of paired serum samples obtained at an
interval of 3e8 weeks. Additionally, Streptococcus pneumo-
niae and Legionella urinary antigen tests could be used from
May 2003. The aetiological diagnostic procedures used and
the treatment administered depended on the attending
physician. Similarly, patientswere hospitalised ormanaged as
outpatient according to the agreement of the patient of their
family and the recommendation of the attending physician.
Covariates
Baseline covariates were age, sex, number of outpatient
visits in previous 2 years, history of hospitalisation for
pneumonia in previous 2 years, history of pneumococcal
vaccination, receipt of influenza vaccine in prior autumn,
smoking (current smoker or not smoker), chronic lung
disease (chronic bronchitis, emphysema or asthma),
chronic heart disease (congestive heart failure or coronary
artery disease), diabetes mellitus, cancer (solid organ or
haematological neoplasia), chronic nephropathy (nephrotic
syndrome, renal failure, dialysis or transplantation),
chronic liver disease (cirrhosis or alcoholic hepatitis), and
long-term corticosteroid therapy.
Statistical analysis
Incidence rates of CAP were calculated as person-years,
considering that in the denominator the total persons-time
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contributed to each individual during the study period.
Event rates were based on the first episode of CAP occurring
during the study period and they do not include multiple
events per person. Chi-squared and Fisher’s tests were used
to calculate p-values in the comparison of categorical
variables, whereas Student’s test and one-way analysis of
variance were used to compare continuous variables.
Multivariable Cox regression analysis with time-varying
covariates was used to calculate hazards ratio (HR) and
estimate the association between baseline conditions and
the time to first outcome during the study period. We
checked for confounders, interactions and multi-
collinearity among the independent variables. The final
model was adjusted by all significant variables, as well as
confounders and other baseline covariables judged of
clinical importance. We assessed the proportional hazards
assumptions adding the covariate by time interactions to
the model and plot the scaled and smoothed Schoenfeld
residuals.19 Statistical significance was set at p < 0.05. The
analyses were performed using Stata/SE version 9.1 (Stata
Corp.).
Results
Incidence rates
The 11,241 cohort members were observed for a total of
33,905 person-years. Overall, 43.5% of the subjects were
male, 55.2% were 65e74 years old, 34.3% were 75e84 years
old and 10.5% were aged 85 years or older at the beginning
of the study. At baseline, the most prevalent co-morbidities
were diabetes mellitus (23.6%), chronic heart disease
(11.9%) and chronic lung disease (11.5%).
During the 40-month study period, a total of 512 indi-
viduals with a first episode of presumptive CAP (380 hospi-
talised and 132 outpatient) were initially identified
according to ICD-9 codes, but only 473 cases (355 hospital-
ised and 118 outpatient) were finally included as radiologi-
cally-confirmed CAP after clinical record review. Incidence
rate was 14 cases per 1000 person-years (10.5 and 3.5 for
hospitalised and outpatient cases, respectively).
Mean incidences of CAP were 11.6 per 1000 among
immunocompetent subjects and 30.9 per 1000 among
immunocompromised patients. Maximum incidences were
observed among patients with chronic lung disease and
long-term corticosteroid therapy (46.5 and 40.1 cases per
1000 person-years, respectively). Table 1 shows time
follow-up, absolute number of CAP cases, and overall
incidence rates according to age, sex and main underlying
conditions.
Microorganisms identified
An aetiological study was carried out in 358 (75.7%) of the
total 473 CAP cases (see footnote a of Table 2). Of the 358
patients with any aetiological evaluation, 131 (36.6%) had
an identifiable (definitive or probable) aetiology. A total of
142 pathogens were identified: a single pathogen in 121
patients, two pathogens in 9 patients and three pathogens
in one patient. Streptococcus pneumoniae was the mostcommon pathogen and accounted for 70 cases (49.3%),
followed by Pseudomonas aeruginosa in 22 (15.5%), Chla-
mydia pneumoniae in 13 (9.2%) and Haemophilus influen-
zae in 8 (5.6%). Table 2 shows the distribution of the total
142 microorganisms identified and diagnostic methods used
for their diagnosis.
Clinical characteristics
Seventy-five percent of CAP episodes were hospitalised and
25% were managed as outpatients. Percentages of CAP
cases requiring hospitalisation did not significantly differ
according to sex or age subgroups. The mean days of hos-
pitalisation was 10.4 days (SD: 8.02). We did not observe
significant differences in the mean length-stay according to
sex or age groups. Twenty (5.6%) of 355 hospitalised CAP
patients were admitted to the intensive care unit (ICU),
with a mean stay of 10.6 days (SD: 9.9).
Of the total 473 CAP cases, 30 (6.3%) had pleural effu-
sion, and 12 (2.5%) had multilobar pneumonia. Overall,
cough was observed in 322 cases (68.1%), fever in 330
(69.8%), dyspnoea in 255 (53.9%), expectoration in 275
(58.1%), pleural pain in 224 (47.4%), and crepitations in 395
(83.5%). An acute altered mental state was observed in 67
patients (14.2%). The association of cough, expectoration
and pleural pain was registered in 135 cases (28.5%).
Table 3 shows results on clinical, exploratory and analyt-
ical data used to estimate PSI. Overall, 73 (15.4%) patients
were assigned to PSI class IeII, 160 (33.8%) were class III, 171
(36.2%) were class IV, and 69 (14.6%) were class V.
Considering 30-day mortality after the diagnosis, there
were 60 deaths from CAP (9 cases due to pneumococcus,
13 due to other microorganisms and 38 caused by unknown
aetiology). Two deaths occurred among CAP cases
managed as outpatient, three deaths of patients in emer-
gency unit before hospitalisation, and 55 deaths among
hospitalised patients. This meant that the overall 30-day
case-fatality rate reached 12.7% (2% for CAP cases
managed as outpatient and 15% for CAP requiring hospi-
talisation). Of the 20 CAP admitted to the ICU, case-
fatality rate was 40% (3 cases due to pneumococcus, 3 due
to other pathogens, and 2 caused by unidentified micro-
organism). No 30-day case-fatality was observed in PSI
class IeII, 11 (6.9%) in PSI class III, 28 (16.4%) in PSI class IV,
and 21 (30.4%) in PSI class V.
Risk factors
In multivariable analysis, the variables most strongly asso-
ciated with increasing risk of CAP were history of hospi-
talisation for CAP in previous 2 years (HR: 3.81; 95%
confidence interval [CI]: 2.64e5.51) and presence of
chronic lung disease (HR: 2.91; 95% CI: 2.35e3.61). Age,
male sex, chronic heart disease, liver disease, cancer and
corticosteroid therapy were also independently associated
with increased risk of CAP. Prior pneumococcal vaccination
was significantly associated with lower risk for CAP (HR:
0.79; 95% CI: 0.64e0.98). Table 4 shows multivariable Cox
regression analysis assessing the association between the
different baseline conditions and risk of CAP in the study
population.
Table 1 Study population, time followed, absolute number of events, and incidence rates of CAP according to age, sex and
underlying conditions among elderly people in Tarragona, Spain (January 1, 2002 to April 30, 2005).
Study population No. of CAP cases Overall CAP incidence
N Person-years Hospitaliseda Outpatientb IRc 95% CId
Age group
65e74 years 6205 19589 145 50 10.0 8.6e11.4
75e84 years 3859 11420 150 43 16.9 14.6e19.4
85 years or more 1176 2896 60 25 29.4 23.5e36.2
Sex
Male 4892 14550 219 61 19.2 17.1e21.6
Female 6348 19355 136 57 10.0 8.6e11.5
Underlying conditions
Chronic lung disease 1298 3674 137 34 46.5 40.0e53.9
Chronic heart disease 1340 3884 77 22 25.5 20.8e30.9
Diabetes mellitus 2650 8014 93 27 15.0 12.4e17.9
Smoking 930 2804 47 11 20.7 15.8e26.7
Cancer 304 821 18 6 29.2 18.8e43.2
Chronic liver disease 215 607 16 3 31.3 19.0e48.5
Chronic renal disease 410 1177 24 8 27.2 18.7e38.1
Corticosteroid therapye 692 1996 61 19 40.1 31.9e49.6
Immunological statusf
Immunocompetents 9794 29760 256 89 11.6 10.4e12.9
Immunocompromised 1446 4145 99 29 30.9 25.8e36.6
Overall total 11240 33905 355 118 14.0 12.7e15.3
a A total of 380 cohort members who had a presumptive episode of hospitalisation for CAP were identified on the basis of the hospital
discharge databases; information on 369 of these events was available for clinical record review, of which 355 were finally validated as
hospitalised CAP cases and 14 were excluded (nosocomial pneumonia or other diagnoses).
b A total of 132 individuals with an episode of presumptive outpatient pneumonia were identified according to ICD-9 pneumonia codes
from emergency or ambulatory visits, but only 118 cases were included as radiologically-confirmed outpatient CAP after review of the
clinical records.
c IR denotes incidence rate of overall CAP (including hospitalised and outpatient cases), and it is calculated per 1000 person-years.
d CI denotes confidence interval.
e Corticosteroid therapy was considered when the patient had received long-term (more than 14 days during 6 months prior study)
corticosteroid therapy (20 mg/day of prednisone or equivalent) for respiratory-related diseases or another immunosuppressive medi-
cation for other illness.
f Immunocompromise was a composite variable defined by the presence of any of the following: cancer, immunodeficiency, renal
disease, liver disease, or long-term corticosteroid therapy.
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CAP is generally considered a major cause of morbidity and
mortality in older adults.2,3 However, because it is not
a reportable illness and a considerable proportion of cases
are managed as outpatient, information about its true
epidemiology can only be obtained from community- or
population-based studies.
In this community-based study, we have analysed the
incidence and epidemiology of CAP among community-
dwelling elderly people in a well-defined geographical area
on the Mediterranean Coast of Spain between 2002 and
2005. To our knowledge, this is the first contemporary study
that provides population-based assessment of incidence
and risk factors for CAP specifically focused on elderly
people in a European country.
The incidence rate of CAP observed in our population (14
cases per 1000 elderly person-years) is much higher than
previously reported in Southern Europe,20e22 but it is,
however, more similar with incidences reported for elderly
persons in Northern Europe and America.5,9,12,23 In Europe,
the reported incidence rates of CAP among the subgroup ofpeople aged 65 years or older varied widely from approxi-
mately 3 cases per 1000 elderly person-years in Spanish and
Italian individuals20e22 to 24 cases per 1000 reported among
Finnish elderly people.23
There are several possible explanations for the different
incidence rate of CAP found in the present study, compared
to previous data from other European Mediterranean
regions, including differences in the study design, study
populations, geographical variations in frequency, and
inclusion criteria of cases. Until now, the apparently low
incidence of CAP in Southern Europe was often explained by
climatic factors. However, mean temperatures that
occurred during our study period were similar to tempera-
tures described in prior studies in the Spanish Mediterra-
nean regions,20,21 so this reason cannot explain the great
difference in the reported incidences. The large differ-
ences in the reported incidences of CAP are probably not
due to true epidemiological differences;more likely they
basically reflect methodological differences between the
studies.
In this study, hospitalisations for CAP were identified on
the basis of first-listed hospital discharge database codes
Table 2 Microorganisms identified (nZ 142) and diag-
nostic methods used in 131 elderly patients with CAPa.
Microorganismb N % Diagnostic
methodsc,d
Streptococcus pneumoniae 70 49.3 10 H, 4 H A,
3 H BS, 1 H PF,
5 BS, 5 BS A, 42 A
Pseudomonas aeruginosa 22 15.5 4 H; 1 H BS, 17 BS
Chlamydia pneumoniae 13 92 13 S
Haemophilus influenzae 8 5.6 8 BS
Staphylococcus aureus 7 4.9 2 H, 5 BS
Legionella 4 2.8 1 S, 3 A
Serratia marcescens 3 2.1 3 BS
Moxarella catharralis 3 2.1 3 BS
Acinetobacter 3 2.1 3 BS
Klebsiella pneumoniae 2 1.4 1 H, 1 BS
Streptococcus sanguis 1 0.7 1 BS
Streptococcus salivaris 1 0.7 1 H
Proteus mirabillis 1 0.7 1 BS
Nocardia asteroides 1 0.7 1 BS
Peptococcus 1 0.7 1 H
Mycobacterium
tuberculosis
1 0.7 1 BS
Coxiella burnetii 1 0.7 1 S
a An aetiological study was carried out in 358 (75.7%) of the
473 CAP. In 355 hospitalised CAP patients, haemoculture was
performed in 278 (78.3%), sputum culture in 189 (53.1%), and
two paired serum serological testing for 98 patients (27.5%). In
outpatient CAP, diagnostic work-up included only haemoculture
for 3 patients (2.4%), sputum culture for 1 patient (0.8%), and
serological tests for 2 patients (1.7%). Urinary antigen tests
were obtained in 119 (25.2%) of all 473 CAP patients, of whom
97 were hospitalised.
b An amount of 135 microorganisms were identified in hospi-
talised CAP, and six microorganisms were identified in outpa-
tient CAP (one case of bacteremic pneumococcal pneumonia
and five cases of nonbacteremic pneumococcal pneumonia with
positive urinary antigen test).
c Diagnostic methods were: haemoculture (H), pleural fluid
culture (PF), bronchoaspirate or sputum culture (BS), serology
(S), urinary antigen test (A).
d Ten cases of CAP were caused by mixed microorganisms:
three cases due to Pneumococcus (1 H A, 2 BS) and Pseudomonas
(1 H, 2 BS); one due to Pneumococcus (A) and Staphylococcus
aureus (BS); one due to Pneumococcus (A) and Chlamydia
pneumoniae (S); one due to Pseudomonas (H) and Staphylo-
coccus aureus (H); one due to Pseudomonas (BS) and Aci-
nectobacter (BS); one due to Peptococcus (H) and Nocardia
(BS); one due to Serratia (BS) and Mycobacterium tuberculosis
(BS); and one due to Chlamydia (S) and Haemophilus (BS).
Table 3 Clinical characteristics and Pneumonia Severity
Index (PSI) observed among 473 elderly patients with
community-acquired pneumonia.
No. (%) 95% CIa
Underlying conditions
Chronic lung disease 171 (36.2) 31.8e40.7
Diabetes mellitus 120 (25.4) 21.5e29.5
Chronic heart disease 99 (20.9) 17.4e24.9
Chronic liver disease 19 (4.0) 2.4e6.2
Cerebrovascular disease 24 (5.1) 3.3e7.5
Chronic renal disease 32 (6.8) 4.7e9.4
Cancer 24 (5.1) 3.3e7.5
Smoking 58 (12.3) 9.5e15.6
Corticosteroid therapy 80 (16.9) 13.7e20.6
Examination findings
Altered mental status 67 (14.2) 11.2e17.6
Temperature <35 C
or 40 C
16 (3.4) 1.9e5.4
Respiratory rate 30/min 36 (7.6) 5.4e10.4
Systolic blood
pressure <90 mmHg
33 (7.0) 4.9e9.7
Pulse 125/min 23 (4.9) 3.1e7.2
Laboratory findingsb
Arterial pH <7.35 46 (10.7) 8.0e14.1
Blood urea
nitrogen 30 mg/dl
91 (21.3) 17.5e25.4
Sodium <130 mmol/l 10 (2.3) 1.1e4.3
Glucose 250 mg/dl 33 (7.7) 5.4e10.7
Haematocrit <30% 22 (5.1) 3.2e7.7
PO2 <60 mmHg 145 (33.9) 29.4e38.6
Radiographic findings
Pleural effusion 30 (6.3) 4.3e8.9
Multilobar condensation 12 (2.5) 1.3e4.4
PSI classc
IeII 73 (15.4) 12.3e19.0
III 160 (33.8) 29.6e38.3
IV 171 (36.2) 31.8e40.7
V 69 (14.6) 11.5e18.1
a CI denotes confidence interval.
b Data were calculated from 428 subjects (excluding 45
outpatient CAP cases without laboratory data).
c Pneumonia Severity Index (PSI): in 45 cases (all of them
managed as outpatient) blood test had not been performed,
and their final PSI score was calculated considering zero points
for every unavailable analytic data.
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checking clinical records, so an overestimation of incidence
is unlikely. In addition, in the present study incidence rates
were based on the first episode of CAP occurring during the
study period and they do not include multiple events per
person, so the total incidence was slightly underestimated
considering that some high-risk persons could have suffered
repeated episodes of CAP, which were not included in the
analysis.
The high rate of hospital admission observed in this
study may be explained by the characteristics of the studycohort (people over 65 years) and the characteristics of the
‘‘Tarragona region’’ where the study was conducted,
particularly in relation to easy accessibility to the refer-
ence hospital, so that many patients sought medical care
directly from the emergency service of the hospital rather
than visiting a primary care physician.
In this study, an aetiological diagnosis was achieved only
in 37% of 358 patients with an aetiological work-up, and this
was relatively low as compared with other studies which
found a causative pathogen in 40e60% of CAP cases.6e11,20e
22 However, most of these studies were hospital case series
and they did not include outpatient CAP (where aetiological
procedures are uncommon).
Table 4 Multivariable Cox regression analysis on risk
factors for suffering CAP among the 11,241 study subjects
according to the presence of baseline conditionsa.
HRb 95% CIc p-Value
Age
65e74 years 1.00 e e
75e84 years 1.61 1.32e1.97 <0.001
85 years or more 2.87 2.20e3.73 <0.001
Sex male 1.24 1.12e1.37 <0.001
History of hospitalisation
for CAP in previous 2 years
3.81 2.64e5.51 <0.001
Chronic lung disease 2.91 2.35e3.61 <0.001
Chronic heart disease 1.46 1.16e1.84 0.001
Diabetes mellitus 1.04 0.85e1.29 0.686
Smoking 1.12 0.83e1.49 0.463
Chronic liver disease 1.82 1.14e2.89 0.012
Cancer 1.56 1.02e2.37 0.039
Chronic renal disease 1.31 0.91e1.88 0.154
Corticosteroid therapy 1.87 1.44e2.41 <0.001
History of anti-pneumococcal
vaccination
0.79 0.64e0.98 0.032
Influenza vaccination
in prior autumn
1.06 0.85e1.31 0.623
a Model adjusted for age, sex, history of hospitalisation for
CAP in previous 2 years, chronic lung disease, chronic heart
disease, diabetes, smoking, cancer, chronic liver disease,
chronic renal disease, corticosteroid therapy, history of prior
pneumococcal vaccination (time-varying condition), receipt of
influenza vaccine in prior autumn (time-varying condition,
confounder with pneumococcal vaccine), and number of
outpatient visits in previous 2 years (continuous).
b HR denotes hazard ratios, and they are calculated for people
who had the listed conditions as compared with those who had
not the condition.
c CI denotes confidence interval.
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microorganism identified in all-age CAP cases, followed by
atypical microorganisms (mainly Mycoplasma pneumoniae
and Chlamydia pneumoniae).1e3 In elderly patients, pneu-
mococcus is also the most common aetiological agent, but
there are discrepancies in different studies regarding the true
incidence of Pseudomonas aeruginosa and Gram-negative
bacilli.6,7,11,24e26 In this study, pneumococcus caused almost
50% of those CAP cases with identified aetiology, whereas
Pseudomonas aeruginosa and Chlamydia pneumoniae were
responsible for 15% and 9% of cases, respectively.
Some recent studies have reported high frequencies of
Pseudomonas aeruginosa causing CAP among older adults
(especially COPD, immunocompromised and nursing-home
patients).26 In our study, 19 of 22 cases involving Pseudo-
monas aeruginosa occurred in COPD patients, and eight
were among patients admitted in the ICU (five of them were
cases with more than one identified microorganism). Our
result fits with data reported by Marin et al. in a large case
series including 4543 American older adults with pneu-
monia, where the occurrence of Pseudomonas aeruginosa
was 17.1% in the community-acquired pneumonia cases and
25.3% in the health care-associated pneumonia cases.26
We emphasise that microbiological investigations were
not consistently applied to all patients in our study butdepended on the attending physician, so a possible bias
linked to microbiological assessment cannot be completely
excluded. In this way, two-paired serologies were per-
formed only in 21% of overall CAP cases and this could
explain why atypical microorganisms were not very
frequent in this study.
Several studies have identified different viruses in 2e
16% of patients with CAP.1,11,13,20 Its frequency depends on
geographical variations and number of aetiological diag-
nostic tests used to research them.1 In this observational
study, no diagnostic tests for viruses were used and this was
a limitation of this study.
Classically, the clinical presentation of CAP in older
adults has been described as quite unspecific and subacute,
with few respiratory symptoms, absence of fever in 40e50%
of cases and a characteristic altered mental state in 20e
40% of patients.2,3,24 Although this is the pre-recognised
presentation, in the current study (likely related to the
inclusion of outpatient CAP cases) respiratory symptoms
and fever were found in most patients whereas a confused
mental state was only found in 14% of patients.
Overall 30-day case-fatality rate was considerable
(12.7%), but it appears in the low limit of case-fatality rates
observed in older adults, where values ranging from 11% to
35% have been reported.1e3,11e13
Regarding data sources, it is known that the quality of
clinical databases is not always as good as desirable. If we
consider indicators about quality of our database codifica-
tions, 92% of cases initially coded as CAP were later
confirmed by checking clinical records. In addition, the
registered prevalences of chronic diseases in the study
population are in accordance with prevalences reported for
Spanish elderly population,11 which supports the validity of
our methods.
The availability of electronic clinical record system for
all participating PHCCs allowed us to define the presence of
underlying conditions among the study population. Thus,
we were able to assess the independent association of
baseline characteristics with risk of CAP in multivariable
analysis. As previously reported among adults, we found
that chronic lung disease, chronic cardiopathy and immu-
nosuppressive medication were independently associated
with increased risk.27e30 In addition, similar to data
reported in community-dwelling elderly individuals in the
USA, we also found that the presence of severe chronic
liver disease, cancer and previous hospitalisations for
pneumonia were also risk factors for CAP among elderly
persons.12 As was already reported,16 prior pneumococcal
vaccination was significantly associated with a low risk of
CAP in the multivariable analysis.
Surprisingly, although incidence rates of CAP were 56%
higher in smokers (20.7 cases per 1000) than in non-
smokers (13.3 per 1000), smoking did not appear as
a significant risk factor in the multivariable analysis. In the
present authors’ opinion, the relatively low proportion of
smokers registered in the clinical records of our elderly
population could be a possible explanation for this unex-
pected finding. Our data point to an independent risk of
CAP associated with being male. Nevertheless, it is
possible that the observed differences in adjusted risks
could be the result of confounding factors unmeasured in
our study population.
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ulation-based, outcome measures and definitions were
based on defined criteria in classical meta-analyses,17,18 and
all cases of CAP were radiographically confirmed and vali-
dated by clinical record review. However, considering that
case findings wereprimarily restricted to hospitalisations or
outpatient visits recorded with an ICD-9 code 480e487 and
a chest radiograph was needed to validate each case, one
limitation of this study could be the possible under-identi-
fication of CAP events. This possible problem is likely to be
more important for CAP treated on an outpatient basis than
in hospitalised cases. It is possible that some ambulatory
patients with mild symptoms were missed because they
were not referred to the hospital or emergency unit for
evaluation, because a chest radiograph was not ordered, or
because pneumonia diagnosis code was not recorded in the
primary care clinical record. In this way, the proportion of
outpatient cases without aetiological diagnostic procedures
was very great and this was also a limitation of the study.
Finally, it must be mentioned that although our study cohort
includes all community-dwelling elderly persons assigned to
eight different PHCCs, the overall study population includes
only persons living in a single geographical area, and the
findings may not be extrapolated to the Spanish population
as a whole. On other hand, given that the study population
comprised community-dwelling individuals, our study
cannot assess the issue of nursing home and health care-
related pneumonia.
In the next years, population-based studies on the inci-
dence and epidemiology of CAP in different settings and
study populations will be needed (especially in high-risk
groups such as elderly people) to clarify the true burden of
the disease, to recognise changes in disease patterns, to
assess preventive interventions and to allocate health care
and research resources, which should be evaluated on the
basis of actual surveillance and incidence data.
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